



**BioNJ C-Suite Virtual Summit**  
**Fridays, October 30 & November 6**

**Navigating Innovation & Uncertainty - With insights from McKinsey & Company**

The advent of COVID-19 has brought unprecedented global disruption and loss in ways never imagined. Equally unprecedented has been the pace at which the life sciences industry is developing medical and technology-driven solutions to combat this devastating virus. Join BioNJ and industry experts to reflect upon observations, learnings and projections, as well as short- and long-term opportunities for medical innovation and the industry overall.

**Agenda – October 30**

8:30 a.m. – 8:40 a.m.	<b>Welcome &amp; Opening Remarks – Debbie Hart, President &amp; CEO - BioNJ</b>
8:40 a.m. – 9:25 a.m.	<b>Keynote: Innovation and New World Order – Stepping Back and Looking Forward</b> <b>McKinsey &amp; Company</b> <i>With incredible uncertainty and unprecedented innovation, let's reflect on the learnings of the past six months and consider the global short- and long-term implications.</i> <b>Featuring Laura Furstenthal, PhD, Senior Partner, McKinsey &amp; Company</b>
9:25 a.m. – 9:30 a.m.	<b>Break / Transition to next session</b>
9:30 a.m. – 10:15 a.m.	<b>Panel: Industry on the Forefront</b> <i>COVID has changed everything. Those on the forefront will discuss what this pandemic has meant, the promise of emerging tests and treatments, and what the future may hold across the healthcare ecosystem.</i> <b>Panelists:</b> <b>Mike Davis, Head, U.S. Neurology, UCB</b> <b>Johanna Mercier, Chief Commercial Officer, Gilead</b> <b>Elaine O'Hara, Head of North America Commercial Operations, Sanofi Pasteur</b> <b>Moderator: Greg Graves, Partner, McKinsey &amp; Company</b>
10:15 a.m. – 10:20 a.m.	<b>Break / Transition to next session</b>
10:20 a.m. – 10:50 a.m.	<b>Fireside Chat: The Regulatory Horizon</b> <i>In a fireside conversation, Dr. Abernethy will discuss how the FDA is responding to COVID and how they have had to pivot to accommodate this new reality and what it might mean moving forward.</i> <b>Featuring Conversationalists:</b> <b>Amy Abernethy, MD, PhD, Principal Deputy Commissioner, Acting CIO, FDA</b> <b>Bruce A. Feinberg - DO, Vice President of Clinical Affairs and Chief Medical Officer, Cardinal Health Specialty Solutions</b>
10:50 a.m. – 10:55 a.m.	<b>Break / Transition to next session</b>
10:55 a.m. – 11:25 a.m.	<b>Fireside Chat: Navigating Innovation &amp; Uncertainty from the Top</b> <i>As an inspiring leader and tireless advocate for the biotechnology industry, Michelle will share her thoughts on industry's mobilization throughout the global pandemic. She will also discuss BIO's BIOEquality agenda and her views on leading BIO during the "new normal" -- a time of daunting challenges and unprecedented promise.</i> <b>Featuring Conversationalists:</b> <b>Michelle McMurry-Heath, MD, PhD, President &amp; CEO, BIO</b> <b>Debbie Hart, President &amp; CEO, BioNJ</b>
11:25 a.m. – 11:30 a.m.	<b>Break / Transition to Face-to-Face Meetup</b>
11:30 a.m. – 12:30 p.m.	<b>Face-to-Face Virtual Meetup – Returning to the Office</b> <i>Are we returning to "work" or returning to the "office" and if so, who and when and how often? What will be the norm six months from now? Will it look anything like six months ago? This panel of senior HR leaders will look at critical operational and organizational challenges and factors such as trust, Wellness, performance management, recruiting, onboarding and so many more realities that Covid has brought on. Please join us and plan to leave with real world, actionable advice.</i> <b>Featuring Chris Cozic, Corporate VP, Global HR, Genmab; Jamie Johnson, Senior Director, HR, Insmad; Martin Rexroad, Sr. VP, HR &amp; Administration, PTC Therapeutics; and Liad Samir, Sr Manager, Talent Acquisition, Leo Pharma; Nicolette Sherman, Chief Human Resources Officer, Oyster Point Pharma</b> <b>Moderated by Jack Levitt, Co-Founder &amp; Principal, LeaderStrong</b>
12:30 p.m.	<b>BioNJ Closing Remarks</b>

## Agenda – November 6

8:30 a.m. – 8:40 a.m.	<b>Welcome &amp; Opening Remarks – Debbie Hart, President &amp; CEO - BioNJ</b>
8:40 a.m. – 9:25 a.m.	<b>Panel: The Financial Environment</b> <i>The industry is navigating the perils of COVID-19 while leading the world to innovate its way out of the pandemic. In this uncertain environment our experts will discuss how capital allocation decisions are being made whether to fund one’s own asset development, M&amp;A or partner.</i> <b>Panelists:</b> Kevin Bitterman, PhD, Partner, Atlas Ventures Derek Hicks, Senior Vice President/Head of Business Development, Spark Therapeutics Daniel Lochner, CFO, Oyster Point Pharma Elizabeth Mily, EVP, Head of Strategy and Business Development, Bristol Myers Squibb <b>Moderator: Arda Ural, PhD, Americas Industry Markets Leader – Life Sciences and Healthcare, EY</b>
9:25 a.m. – 9:30 a.m.	<b>Break / Transition to next session</b>
9:30 a.m. – 10:15 a.m.	<b>Panel: COVID – Driven Technology Transformation and the Patient</b> <i>This panel will consider the legal, regulatory, insurer, PCP relationship implications of virtual care and telehealth platforms, including ways biopharma companies can promote better outcomes and experience.</i> <b>Panelists:</b> Anupam Girdhar, Vice President and General Manager, Clinical Vertical – Genetic Sciences Division, Thermo Fisher Scientific Innes Meldrum, SVP & Chief Commercial Officer, Otsuka Patricia Obermaier, Vice President, U.S. Health & Life Sciences, Microsoft Linda Schwimmer, President and CEO, New Jersey Health Care Quality Institute <b>Moderator: Michele Buenafe, Partner, Morgan, Lewis &amp; Bockius LLP</b>
10:15 a.m. – 10:20 a.m.	<b>Break /Transition to next session</b>
10:20 a.m. – 10:50 a.m.	<b>Fireside Chat: Data Analytics and Solving for the Future</b> <i>With a birds’ eye view, this conversation will feature reflections on the challenges and opportunities that COVID is creating, and how the industry can use this period to further accelerate digital &amp; analytics priorities.</i> <b>Featuring Conversationalists:</b> Dave Williams, Chief Information & Digital Officer, Merck Daniel Garen, Partner, DLA Piper
10:50 a.m. – 10:55 a.m.	<b>Break / Transition to next session</b>
10:55 a.m. – 11:25 a.m.	<b>Fireside Chat: The “New Normal” - Transition, Recovery and Beyond</b> <i>Moderna is on a very short list of companies leading the way in the development of a vaccine against COVID-19. During this Fireside Chat, we will hear from two Moderna vanguards sharing their experience and their insights...looking back to inform the future.</i> <b>Featuring Conversationalists:</b> Francois Nader, MD, Board Director, Moderna Tal Zaks, MD, Chief Medical Officer, Moderna
11:25 a.m. – 11:30 a.m.	<b>Break / Transition to Face-To-Face Meetup</b>
11:30 a.m. – 12:30 p.m.	<b>Face-to-Face Virtual Meetup</b> <i>Just three days after the November election when some of the results may still be unknown, renowned political commentator David Wasserman of the Cook Political Report will provide insights and analysis on the 2020 election during what is sure to be a lively and interesting session...all delivered in a strictly nonpartisan way.</i> <b>Featuring David Wasserman, U.S. House Editor at Cook Political Report Introduced by Michele Oshman, Vice President, External Relations, BIO</b>
12:30 p.m.	<b>BioNJ Closing Remarks</b>